Innovative Utilization of Real-World Evidence (RWE) in Early Heart Failure Drug Development

Time: 1:00 pm
day: Day Two

Details:

• Highlight the rationale and benefits of incorporating Real-World Evidence (RWE) early in drug development to understand disease burden and unmet needs, ensuring a strong foundation for clinical programs.
• Discuss how RWE supports the identification and validation of meaningful clinical endpoints, with case studies demonstrating its impact on endpoint selection and trial success.
• Explore the role of RWE in providing external control arms for early-phase clinical trials, showcasing examples of successful applications and their influence on trial design and outcomes.